Form 4: Maze Therapeutics Executive Sells Shares After Option Exercise

Maze Therapeutics' President of R&D & CMO, Harold Bernstein, exercised stock options and subsequently sold shares totaling 4,844 units in early January 2026, pursuant to a pre-arranged 10b5-1 trading plan.

Summary

• Harold Bernstein, President, R&D & CMO of Maze Therapeutics, Inc., reported transactions involving the company's common stock.
• On January 2, 2026, Bernstein exercised options to acquire 4,432 shares of common stock at an exercise price of $10.42 per share.
• Immediately following, he sold these 4,432 shares at a weighted average price of $40.4304 per share, with individual sales ranging from $40.00 to $40.965.
• On January 5, 2026, Bernstein exercised options to acquire an additional 412 shares of common stock at an exercise price of $10.42 per share.
• These 412 shares were then sold at a price of $40.00 per share.
• All reported transactions were conducted under a Rule 10b5-1 trading plan established by Bernstein on September 29, 2025.
• Following these specific transactions, Bernstein's direct beneficial ownership of the common stock acquired and immediately sold is 0, but he retains 337,563 derivative securities (stock options).

Sentiment

Score: 6

Explanation: The filing reports routine insider transactions (option exercise and sale) executed under a pre-established 10b5-1 trading plan. While the executive is realizing significant gains, which is positive for the individual, the sale of shares by an insider can be viewed neutrally or with slight caution by the market.

Positives

• The executive realized significant gains from option exercises and sales, indicating a substantial increase in the company's stock price above the option exercise price of $10.42.

Negatives

• A key executive reduced their direct equity holdings in the company by selling 4,844 shares, which can sometimes be perceived negatively by the market, even when pre-scheduled.

Future Outlook

NA

Industry Context

NA

Stakeholder Impact

• Shareholders may view the executive's share sale as a signal, though mitigated by the pre-established 10b5-1 plan. The executive realizing significant gains could be seen as a positive indicator of past stock performance.

Next Steps

• Continued monthly vesting of remaining stock options at 1/48th of the total award, subject to the reporting person's continued service.

Key Dates

Recommendation

The filing details an executive's pre-scheduled exercise of stock options and subsequent sale of shares, a routine transaction under a 10b5-1 plan. This type of disclosure typically does not provide sufficient fundamental or strategic information to warrant a change in investment recommendation. The executive realizing gains is positive for the individual, but the sale itself is a neutral event for the company's valuation.

Keywords

Insider trading, Form 4, stock options, equity sale, executive compensation, Maze Therapeutics, MAZE, Harold Bernstein, 10b5-1 plan